Covid-19

The pathology technology sector has moved incredibly quickly to develop, manufacture and supply testing devices for detecting COVID-19 infections and identifying the SARS-CoV-2 virus. Within 8 weeks of the virus becoming a significant human threat, the first commercial tests were available to detect COVID-19 infection in humans. The pathology technology suppliers are a key part of a broader ecosystem that includes the pathologist, scientists, lab staff and sample collection teams in hospital and commercial labs. It includes the community medical services where point of care testing is conducted. Of key importance in the COVID-19 example are research scientists at medical research institutes such as the Peter Doherty Centre. It is in centers like these that the basic research is completed which is often the initiator for production of commercial test products.

The technology provided by Pathology Technology Australia members is critical to these research center, for without it, none of their valuable work can be done. This page aims to provide up to date information on health testing in the COVID-19 pandemic. We will cover many facets of the pathology technology so vital to testing human health in laboratories, hospitals, medical clinics and at home.